References
- Headache Classification of the International Headache Society. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:627–808.
- Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(2017):1211–1259.
- Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19:17.
- Steiner TJ, Birbeck GL, Jensen RH, et al. Headache disorders are third cause of disability worldwide. J Headache Pain. 2015;16:58.
- Affaitati G, Martelletti P, Lopopolo M, et al. Use of nonsteroidal anti-inflammatory drugs for symptomatic treatment of episodic headache. Pain Pract. 2017;17(3):392–401.
- Belvis R, Mas N, Aceituno A. Migraine attack treatment: a tailor-made suit, not one size fits all. Recent Pat CNS Drug Discov. 2014;9(1):26–40.
- Giamberardino MA, Martelletti P. Emerging drugs for migraine treatment. Expert Opin Emerg Drugs. 2015;20(1):137–147.
- Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3–20.
- Bartolini M, Giamberardino MA, Lisotto C, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain. 2011;12(3):361–368.
- Capo A, Affaitati G, Giamberardino MA, et al. Psoriasis and migraine. J Eur Acad Dermatol Venereol. 2018;32(1):57–61.
- Giamberardino MA, Affaitati G, Costantini R. Visceral referred pain. J Musculoske Pain. 2010;18(4):403–410.
- Giamberardino MA, Affaitati G, Martelletti P, et al. Impact of migraine on fibromyalgia symptoms. J Headache Pain. 2015;17:28.
- Costantini R, Affaitati G, Wesselmann U, et al. Visceral pain as a triggering factor for fibromyalgia symptoms in comorbid patients. Pain. 2017;158(10):1925–1937.
- Giamberardino MA, Tana C, Costantini R. Pain thresholds in women with chronic pelvic pain. Curr Opin Obstet Gynecol. 2014;26(4):253–259.
- Giamberardino MA, Vecchiet L. Visceral pain, referred hyperalgesia and outcome: new concepts. Eur J Anaesthesiol Suppl. 1995;10:61–66.
- Tana C, Tafuri E, Tana M, et al. New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain. 2013;14:9.
- Holland PR, Goadsby PJ. Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics. 2018;15(2):304–312.
- Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018;11:515–526.
- Martelletti P. Acute treatment of migraine: quo vadis? Expert Opin Pharmacother. 2017;18(11):1035–1037.
- Benemei S, Fusi C, Trevisan G, et al. The TRPA1 channel in migraine mechanism and treatment. British J Pharmacol. 2014;171:2552–2567.
- Pj G, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. N Engl J Med. 2002;346(4):257–270.
- Hoffmann J, Goadsby PJ. Emerging targets in migraine. CNS Drugs. 2014;28:11–17.
- Labruijere S, Ibrahimi K, Chan KY, et al. Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies. Expert Opin Drug Discov. 2013;8(11):1309–1323.
- Vollbracht S, Rapoport AM. The pipeline in headache therapy. CNS Drugs. 2013;27(9):717–729.
- Tfelt-Hansen P, Olesen J. Taking the negative view of current migraine treatments: the unmet needs. CNS Drugs. 2012;26(5):375–382.
- Costantini R, De Nicola P, Bianco F, et al. Tumor vs non-tumor origin of occult and obscure gastrointestinal bleeding requiring hospitalization. Tumori. 2007;93(5):461–466.
- Joshi S, Rapoport AM. Diclofenac potassium for oral solution (CAMBIA®) in the acute management of a migraine attack: clinical evidence and practical experience. Ther Adv Neurol Disord. 2017;10(4):217–226.
- Silberstein SD, Stirpe JC. COX inhibitors for the treatment of migraine. Expert Opin Pharmacother. 2014;15(13):1863–1874.
- Welch KM, Ellis DJ, Pa K. Successful migraine prophylaxis with naproxen sodium. Neurology. 1985;35(9):1304–1310.
- Giamberardino MA, Affaitati G, Costantini R, et al. Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. J Pain Res. 2017;10:2751–2760.
- Giamberardino MA, Affaitati G, Curto M, et al. Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med. 2016;11(8):1045–1057.
- Giamberardino MA, Costantini R. Challenging chronic migraine: targeting the CGRP receptor. Lancet Neurol. 2017;16(6):410–411.
- Ho TW, Ho AP, Ge YJ, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia. 2016;36(2016):148–161.
- Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83(2014):958–966.
- Messina R, Goadsby PJ. CGRP - a target for acute therapy in migraine: clinical data. Cephalalgia. 2018 Jan;1:333102418768095. Epub ahead of print.
- A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine. [cited 2018 Sept 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT01657370.
- Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36(9):887–898.
- Efficacy, safety, and tolerability study of oral ubrogepant in the acute treatment of migraine. [cited 2018 Sept 12]. Available from: https://clinicaltrials.gov/show/NCT02828020.
- ACHIEVE I: Ubrogepant Meets Endpoints for Acute Migraine. Medscape medical news. American Academy of Neurology (AAN) 2018 Annual Meeting; 2018 Apr 21–27; Los Angeles, California. Available from: https://www.medscape.com/viewcollection/34388
- Alpha-Efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine. [cited 2018 Sept 12]. Available from: https://clinicaltrials.gov/show/NCT02867709.
- Ubrogepant Safe, Effective for Migraine in Second Phase 3 Trial. [cited 2018 Sept 12]. Available from: https://www.medscape.com/viewarticle/895951.
- An extension study to evaluate the long-term safety and tolerability of ubrogepant in the treatment of migraine. [cited 2018 Sept 12]. Available from: https://clinicaltrials.gov/show/NCT02873221.
- Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34(2014):114–125. Available from: https://clinicaltrials.gov/show/NCT01430442
- Open label safety study in acute treatment of migraine. [cited 2018 Sept 12]. Available from: https://clinicaltrials.gov/show/NCT03266588.
- Safety and efficacy study in adult subjects with acute migraines. [cited 2018 Sept 12]. Available from: https://clinicaltrials.gov/show/NCT03235479.
- Safety and efficacy in adult subjects with acute migraines. [cited 2018 Sept 12]. Available from: https://clinicaltrials.gov/show/NCT03237845.
- Rb L, Conway CM, Stock EG, et al. Efficacy, safety and tolerability or rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: results from a phase 3, double-blind, randomized, placebo-controlled trial, study 301. [cited 2018 Sept 12]. Available from: http://biohavenpharma.com/wpcontent/uploads/2018/06/Rimegepant-Phase-3-Study-301_AHS-2018-Late-BreakingPoster-Presentation-1.pdf
- Rb L, Coric V, Stock EG, et al. Efficacy, safety and tolerability of Rimegepant 75mg, an oral CGRP receptor atagonist, for the acute treatment of migraine: results from a phase3, double-blind, randomized, placebo-controlled trial, study 302. [cited 2018 Sept 12]. Available from: http://biohavenpharma.com/wpcontent/uploads/2018/06/Rimegepant-Phase-3-Study-302_AHS-2018-Late-BreakingPlatform-Presentation-1.pdf
- Croop R, Ivans A, Stock D, et al. A Phase 1 study to evaluate the bioequivalence of oral tablet and orally dissolving tablet formulations of rimegepant in healthy adult subjects under fasting conditions.[cited 2018 Sept 12]. Available from: http://biohavenpharma.com/wpcontent/uploads/2018/06/Rimegepant-Zydis-ODT-Bioequivalence-Phase-1-Study_AHS2018-Late-Breaking-Poster-Presentation-1.pdf
- BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine. [cited 2018 Oct 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT03461757.
- Färkkilä M, Diener HC, Géraud G, et al. COL MIG-202 study group. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405–413.